According to an article recently published in the Annals of Oncology, treatment consisting of Doxil® (pegylated liposomal doxorubicin) and Paraplatin® (carboplatin) may improve survival in patients with relapsed ovarian cancer.
Ovarian cancer is the leading cause of gynecologic cancer-related death in the United States. Relapsed ovarian cancer refers to cancer that has returned or progressed following prior therapies. Taxanes and platinums are types of chemotherapy agents commonly used in the treatment of ovarian cancer. Once patients with ovarian cancer have relapsed following taxanes and platinums, treatment options are limited.
Doxil is a class of chemotherapy agents referred to as an anthracycline. Doxil is specifically created to deliver more of the chemotherapy agent to the cancer cells rather than to healthy tissues. As a result, side effects from the active ingredient in Doxil are limited while the agent’s anticancer activity is maintained.
Researchers from France recently conducted a clinical trial to evaluate Doxil plus Paraplatin in the treatment of patients with advanced ovarian cancer that had relapsed following prior platinum and taxane-based regimens.
- Anticancer responses occurred in 63% of patients.
- Complete disappearances of cancer occurred in 38% of patients.
- Median progression-free survival was 9.4 months.
- Median overall survival was 32 months.
The researchers concluded that the combination of Doxil/Paraplatin appears highly effective for women with ovarian cancer that has relapsed following prior taxane and platinum-based therapies. The authors stated, “Evaluationof this regimen in Phase III trials is warranted.”
Patients with relapsed ovarian cancer may wish to speak with their physician regarding their individual risks and benefits of participating in a clinical trial further evaluating Doxil/Paraplatin or other novel therapeutic approaches. Two sources of information regarding ongoing clinical trials include the National Cancer Institute (www.cancer.gov) and www.eCancerTrials.com.
Reference: Ferrero J-M, Weber B, Geay J-F, et al. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO Phase II trial. Annals of Oncology. 2007; 18: 263-268.